Pfizer set about evaluating inclacumab in pair of phase 3 studies, dubbed Thrive. The Big Pharma terminated one of those ...

Inclacumab, which Pfizer obtained in its 2022 acquisition of Global Blood Therapeutics, failed to significantly lower pain ...

By Padmanabhan Ananthan (Reuters) -In the latest setback for Pfizer's sickle cell anemia treatments, experimental drug ...

An experimental Pfizer sickle cell treatment failed to meet the main goal in a late-stage trial for patients aged 16 and ...

Global Blood Therapeutics novel sickle cell disease drug, Oxbryta, continues to outperform revenue expectations early in its launch despite the "pandemic era". It is evident in both the data and ...

Global Blood Therapeutics provided investors with a preliminary update from its phase 3 HOPE study. This 154-patient trial is testing its drug Voxelotor as a treatment for kids with sickle cell ...

The all-cash deal will see Pfizer acquire all outstanding shares of Global Blood Therapeutics for $68.50 per share; all told, the enterprise value of the arrangement is roughly $5.4 billion.

Global Blood Therapeutics is on track to start a Phase II study by mid-year. So, it is possible that Oxbryta’s biggest competition is actually in-house. GBT Pipeline (GBT) ...

Global Blood Therapeutics (NASDAQ: GBT) shares took a big dive on Tuesday, sliding to close more than 14% lower. Investors weren't happy that the company is launching a big new round of financing.

What happened Shares of hematology biotech Global Blood Therapeutics(GBT) are up 16.5% as of 10:30 a.m. EDT after the company posted upbeat second-quarter 2021 earnings.

The global blood cancer therapeutics market is poised to grow by USD 12.63 billion during 2019-2023, progressing at a CAGR of over 8%.

Global Blood Therapeutics provided investors with a preliminary update from its phase 3 HOPE study. This 154-patient trial is testing its drug Voxelotor as a treatment for kids with sickle cell ...